EGFR and hepatocellular carcinoma: We have previously shown that dysregulation of GALNT2 contributes to the malignant progression of hepatocellular carcinoma and oral squamous carcinoma cells by modifying glycosylation of the epidermal growth factor receptor, a member of receptor tyrosine kinase (RTK) family [6,7].